RiboQuark Pharmaceutical Technology Co., Ltd., Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007

KUNSHAN, China--(BUSINESS WIRE)--Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. (“RiboQuark”), a Chinese-foreign equity joint venture and clinical stage pharmaceutical company established by Suzhou Ribo Life Science Co., Ltd. (“Ribo”) and Quark Pharmaceuticals Inc., announced today enrollment of the first patient in China in QRK207, a global pivotal Phase II/III study of the ocular neuroprotectant QPI-1007. QPI-1007 is a synthetic siRNA designed to temporarily inhibit expression of the p

Full Story →